마이크로바이옴 치료제 시장 규모, 시장 점유율, 용도 분석, 지역별 전망, 성장 동향, 주요 기업, 경쟁 전략, 예측(2023-2031년)

Microbiome Therapeutics Market is Expected to Grow at 32% by 2031. Microbiome therapeutics market is an emerging market with abundant opportunities in today's world. During the forecast period market experts suggest that number of products currently involved in clinical trials proves the amount of research and development activities carried out across the world focusing on microbiome therapeutics. Considering the structure of the microbiome market the potential is quite large. The key factors assisting the growth of this market comprise rising geriatric population, increasing incidences of lifestyle diseases, increasing demand for treatments with high efficiency and low side effects. The major factors that are expected to restrain the growth of this market are lack of broad research to aid the market pull, low awareness among the population related to the efficient usage and effect of prebiotics and probiotics, and impending government regulations on probiotics and prebiotics. The segmentation of microbiome market comprises of type of drugs, diseases, and geography.

Market experts suggest that the microbial landscape of human body has attracted more than US$ 650 Mn since 2010. In recent years, probiotics, or beneficial gut bacteria therapy, have been popular. These products possess capacity of preventing number of diseases by restoring the human microbiome to its natural state. However, the overall microbiome therapeutics market is still in its infancy; hence, cannot be used as a replacement for medication or as a treatment for the eradication of the disease. Europe was observed as the leading regional market for microbiome therapeutics followed by North America. The key factors assisting the microbiome therapeutics market in Europe are due to high acceptance and rising awareness of probiotic and prebiotic products. Asia-Pacific was observed as the most potential region in terms of population and prevalence of disease throughout the forecast period.

Key Players Identified for Microbiome Therapeutics Market Include but are Not Limited to:

OpenBiome, Seres Therapeutics Inc., 4D Pharma plc., Locus Biosciences, Inc., Enterome SA, Finch Therapeutics Group, Inc., Intralytix, Inc., Microbiotica, Second Genome, Rebiotix Inc., Vedanta Bioscience, Inc. And Other Notable Players.

Historical & Forecast Period

This study report represents analysis of each segment from 2021 to 2031 considering 2022 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2031.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Microbiome Therapeutics market are as follows:

• Research and development budgets of manufacturers and government spending

• Revenues of key companies in the market segment

• Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report:

Micro and macro environment factors that are currently influencing the Microbiome Therapeutics market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Type

• FMT
• Microbiome Drugs

Application

• C. difficile
• Crohn's disease
• Inflammatory Bowel Disease
• Diabetes
• Others

Region Segment (2021-2031; US$ Million)

• North America
  • U.S.
  • Canada
  • Rest of North America

• UK and European Union
  • UK
  • Germany
  • Spain
  • Italy
  • France
  • Rest of Europe

• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific

• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America

• Middle East and Africa
  • GCC
  • Africa
  • Rest of Middle East and Africa

Key questions answered in this report:

• What are the key micro and macro environmental factors that are impacting the growth of Microbiome Therapeutics market?

• What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?

• Estimated forecast and market projections up to 2031.

• Which segment accounts for the fastest CAGR during the forecast period?

• Which market segment holds a larger market share and why?

• Are low and middle-income economies investing in the Microbiome Therapeutics market?

• Which is the largest regional market for Microbiome Therapeutics market?

• What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?

• Which are the key trends driving Microbiome Therapeutics market growth?

• Who are the key competitors and what are their key strategies to enhance their market presence in the Microbiome Therapeutics market worldwide?

Table of Contents

1. Preface

• 1.1. Report Description
  • 1.1.1. Purpose of the Report
  • 1.1.2. Target Audience
  • 1.1.3. Key Offerings
• 1.2. Market Segmentation
• 1.3. Research Methodology
  • 1.3.1. Phase I - Secondary Research
  • 1.3.2. Phase II - Primary Research
  • 1.3.3. Phase III - Expert Panel Review
  • 1.3.4. Assumptions
  • 1.3.5. Approach Adopted

2. Executive Summary

• 2.1. Market Snapshot: Global Microbiome Therapeutics Market
• 2.2. Global Microbiome Therapeutics Market, By Type, 2022 (US$ Million)
• 2.3. Global Microbiome Therapeutics Market, By Application, 2022 (US$ Million)
• 2.4. Global Microbiome Therapeutics Market, By Geography, 2022 (US$ Million)
• 2.5. Attractive Investment Proposition by Geography, 2022

3. Microbiome Therapeutics Market: Competitive Analysis

• 3.1. Market Positioning of Key Microbiome Therapeutics Market Vendors
• 3.2. Strategies Adopted by Microbiome Therapeutics Market Vendors
• 3.3. Key Industry Strategies
• 3.4. Tier Analysis 2022 Versus 2031

4. Microbiome Therapeutics Market: Macro Analysis & Market Dynamics

• 4.1. Introduction
• 4.2. Global Microbiome Therapeutics Market Value, 2021 - 2031, (US$ Million)
• 4.3. Market Dynamics
  • 4.3.1. Market Drivers
  • 4.3.2. Market Restraints
  • 4.3.3. Key Challenges
  • 4.3.4. Key Opportunities
• 4.4. Impact Analysis of Drivers and Restraints
• 4.5. See-Saw Analysis

5. Microbiome Therapeutics Market: By Type, 2021-2031, USD (Million)

• 5.1. Market Overview
• 5.2. Growth & Revenue Analysis: 2022 Versus 2031
• 5.3. Market Segmentation
  • 5.3.1. FMT
  • 5.3.2. Microbiome Drugs

6. Microbiome Therapeutics Market: By Application, 2021-2031, USD (Million)

• 6.1. Market Overview
• 6.2. Growth & Revenue Analysis: 2022 Versus 2031
• 6.3. Market Segmentation
  • 6.3.1. C. difficile
  • 6.3.2. Crohn's disease
  • 6.3.3. Inflammatory Bowel Disease
  • 6.3.4. Diabetes
  • 6.3.5. Others

7. North America Microbiome Therapeutics Market, 2021-2031, USD (Million)

• 7.1. Market Overview
• 7.2. Microbiome Therapeutics Market: By Type, 2021-2031, USD (Million)
• 7.3. Microbiome Therapeutics Market: By Application, 2021-2031, USD (Million)
• 7.4.Microbiome Therapeutics Market: By Region, 2021-2031, USD (Million)
  • 7.4.1.North America
    • 7.4.1.1. U.S.
      • 7.4.1.1.1. Microbiome Therapeutics Market: By Type, 2021-2031, USD (Million)
      • 7.4.1.1.1. Microbiome Therapeutics Market: By Application, 2021-2031, USD (Million)
    • 7.4.1.2. Canada
      • 7.4.1.2.1. Microbiome Therapeutics Market: By Type, 2021-2031, USD (Million)
      • 7.4.1.2.1. Microbiome Therapeutics Market: By Application, 2021-2031, USD (Million)
    • 7.4.1.3. Rest of North America
      • 7.4.1.3.1. Microbiome Therapeutics Market: By Type, 2021-2031, USD (Million)
      • 7.4.1.3.1. Microbiome Therapeutics Market: By Application, 2021-2031, USD (Million)

8. UK and European Union Microbiome Therapeutics Market, 2021-2031, USD (Million)

• 8.1. Market Overview
• 8.2. Microbiome Therapeutics Market: By Type, 2021-2031, USD (Million)
• 8.3. Microbiome Therapeutics Market: By Application, 2021-2031, USD (Million)
• 8.4.Microbiome Therapeutics Market: By Region, 2021-2031, USD (Million)
  • 8.4.1.UK and European Union
    • 8.4.1.1. UK
      • 8.4.1.1.1. Microbiome Therapeutics Market: By Type, 2021-2031, USD (Million)
      • 8.4.1.1.1. Microbiome Therapeutics Market: By Application, 2021-2031, USD (Million)
    • 8.4.1.2. Germany
      • 8.4.1.2.1. Microbiome Therapeutics Market: By Type, 2021-2031, USD (Million)
      • 8.4.1.2.1. Microbiome Therapeutics Market: By Application, 2021-2031, USD (Million)
    • 8.4.1.3. Spain
      • 8.4.1.3.1. Microbiome Therapeutics Market: By Type, 2021-2031, USD (Million)
      • 8.4.1.3.1. Microbiome Therapeutics Market: By Application, 2021-2031, USD (Million)
    • 8.4.1.4. Italy
      • 8.4.1.4.1. Microbiome Therapeutics Market: By Type, 2021-2031, USD (Million)
      • 8.4.1.4.1. Microbiome Therapeutics Market: By Application, 2021-2031, USD (Million)
    • 8.4.1.5. France
      • 8.4.1.5.1. Microbiome Therapeutics Market: By Type, 2021-2031, USD (Million)
      • 8.4.1.5.1. Microbiome Therapeutics Market: By Application, 2021-2031, USD (Million)
    • 8.4.1.6. Rest of Europe
      • 8.4.1.6.1. Microbiome Therapeutics Market: By Type, 2021-2031, USD (Million)
      • 8.4.1.6.1. Microbiome Therapeutics Market: By Application, 2021-2031, USD (Million)

9. Asia Pacific Microbiome Therapeutics Market, 2021-2031, USD (Million)

• 9.1. Market Overview
• 9.2. Microbiome Therapeutics Market: By Type, 2021-2031, USD (Million)
• 9.3. Microbiome Therapeutics Market: By Application, 2021-2031, USD (Million)
• 9.4.Microbiome Therapeutics Market: By Region, 2021-2031, USD (Million)
  • 9.4.1.Asia Pacific
    • 9.4.1.1. China
      • 9.4.1.1.1. Microbiome Therapeutics Market: By Type, 2021-2031, USD (Million)
      • 9.4.1.1.1. Microbiome Therapeutics Market: By Application, 2021-2031, USD (Million)
    • 9.4.1.2. Japan
      • 9.4.1.2.1. Microbiome Therapeutics Market: By Type, 2021-2031, USD (Million)
      • 9.4.1.2.1. Microbiome Therapeutics Market: By Application, 2021-2031, USD (Million)
    • 9.4.1.3. India
      • 9.4.1.3.1. Microbiome Therapeutics Market: By Type, 2021-2031, USD (Million)
      • 9.4.1.3.1. Microbiome Therapeutics Market: By Application, 2021-2031, USD (Million)
    • 9.4.1.4. Australia
      • 9.4.1.4.1. Microbiome Therapeutics Market: By Type, 2021-2031, USD (Million)
      • 9.4.1.4.1. Microbiome Therapeutics Market: By Application, 2021-2031, USD (Million)
    • 9.4.1.5. South Korea
      • 9.4.1.5.1. Microbiome Therapeutics Market: By Type, 2021-2031, USD (Million)
      • 9.4.1.5.1. Microbiome Therapeutics Market: By Application, 2021-2031, USD (Million)
    • 9.4.1.6. Rest of Asia Pacific
      • 9.4.1.6.1. Microbiome Therapeutics Market: By Type, 2021-2031, USD (Million)
      • 9.4.1.6.1. Microbiome Therapeutics Market: By Application, 2021-2031, USD (Million)

10. Latin America Microbiome Therapeutics Market, 2021-2031, USD (Million)

• 10.1. Market Overview
• 10.2. Microbiome Therapeutics Market: By Type, 2021-2031, USD (Million)
• 10.3. Microbiome Therapeutics Market: By Application, 2021-2031, USD (Million)
• 10.4.Microbiome Therapeutics Market: By Region, 2021-2031, USD (Million)
  • 10.4.1.Latin America
    • 10.4.1.1. Brazil
      • 10.4.1.1.1. Microbiome Therapeutics Market: By Type, 2021-2031, USD (Million)
      • 10.4.1.1.1. Microbiome Therapeutics Market: By Application, 2021-2031, USD (Million)
    • 10.4.1.2. Mexico
      • 10.4.1.2.1. Microbiome Therapeutics Market: By Type, 2021-2031, USD (Million)
      • 10.4.1.2.1. Microbiome Therapeutics Market: By Application, 2021-2031, USD (Million)
    • 10.4.1.3. Rest of Latin America
      • 10.4.1.3.1. Microbiome Therapeutics Market: By Type, 2021-2031, USD (Million)
      • 10.4.1.3.1. Microbiome Therapeutics Market: By Application, 2021-2031, USD (Million)

11. Middle East and Africa Microbiome Therapeutics Market, 2021-2031, USD (Million)

• 11.1. Market Overview
• 11.2. Microbiome Therapeutics Market: By Type, 2021-2031, USD (Million)
• 11.3. Microbiome Therapeutics Market: By Application, 2021-2031, USD (Million)
• 11.4.Microbiome Therapeutics Market: By Region, 2021-2031, USD (Million)
  • 11.4.1.Middle East and Africa
    • 11.4.1.1. GCC
      • 11.4.1.1.1. Microbiome Therapeutics Market: By Type, 2021-2031, USD (Million)
      • 11.4.1.1.1. Microbiome Therapeutics Market: By Application, 2021-2031, USD (Million)
    • 11.4.1.2. Africa
      • 11.4.1.2.1. Microbiome Therapeutics Market: By Type, 2021-2031, USD (Million)
      • 11.4.1.2.1. Microbiome Therapeutics Market: By Application, 2021-2031, USD (Million)
    • 11.4.1.3. Rest of Middle East and Africa
      • 11.4.1.3.1. Microbiome Therapeutics Market: By Type, 2021-2031, USD (Million)
      • 11.4.1.3.1. Microbiome Therapeutics Market: By Application, 2021-2031, USD (Million)

12. Company Profile

• 12.1. OpenBiome
  • 12.1.1. Company Overview
  • 12.1.2. Financial Performance
  • 12.1.3. Product Portfolio
  • 12.1.4. Strategic Initiatives
• 12.2. Seres Therapeutics Inc.
  • 12.2.1. Company Overview
  • 12.2.2. Financial Performance
  • 12.2.3. Product Portfolio
  • 12.2.4. Strategic Initiatives
• 12.3. 4D Pharma plc.
  • 12.3.1. Company Overview
  • 12.3.2. Financial Performance
  • 12.3.3. Product Portfolio
  • 12.3.4. Strategic Initiatives
• 12.4. Locus Biosciences, Inc.
  • 12.4.1. Company Overview
  • 12.4.2. Financial Performance
  • 12.4.3. Product Portfolio
  • 12.4.4. Strategic Initiatives
• 12.5. Enterome SA
  • 12.5.1. Company Overview
  • 12.5.2. Financial Performance
  • 12.5.3. Product Portfolio
  • 12.5.4. Strategic Initiatives
• 12.6. Finch Therapeutics Group, Inc.
  • 12.6.1. Company Overview
  • 12.6.2. Financial Performance
  • 12.6.3. Product Portfolio
  • 12.6.4. Strategic Initiatives
• 12.7. Intralytix, Inc.
  • 12.7.1. Company Overview
  • 12.7.2. Financial Performance
  • 12.7.3. Product Portfolio
  • 12.7.4. Strategic Initiatives
• 12.8. Microbiotica
  • 12.8.1. Company Overview
  • 12.8.2. Financial Performance
  • 12.8.3. Product Portfolio
  • 12.8.4. Strategic Initiatives
• 12.9. Second Genome
  • 12.9.1. Company Overview
  • 12.9.2. Financial Performance
  • 12.9.3. Product Portfolio
  • 12.9.4. Strategic Initiatives
• 12.10. Rebiotix Inc.
  • 12.10.1. Company Overview
  • 12.10.2. Financial Performance
  • 12.10.3. Product Portfolio
  • 12.10.4. Strategic Initiatives
• 12.11. Vedanta Bioscience, Inc.
  • 12.11.1. Company Overview
  • 12.11.2. Financial Performance
  • 12.11.3. Product Portfolio
  • 12.11.4. Strategic Initiatives
• 12.12. Other Notable Players
  • 12.12.1. Company Overview
  • 12.12.2. Financial Performance
  • 12.12.3. Product Portfolio
  • 12.12.4. Strategic Initiatives